Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Virchows Arch ; 2015 Oct 19.
Article in English | MEDLINE | ID: mdl-26481244

ABSTRACT

Digital image analysis (DIA) enables higher accuracy, reproducibility, and capacity to enumerate cell populations by immunohistochemistry; however, the most unique benefits may be obtained by evaluating the spatial distribution and intra-tissue variance of markers. The proliferative activity of breast cancer tissue, estimated by the Ki67 labeling index (Ki67 LI), is a prognostic and predictive biomarker requiring robust measurement methodologies. We performed DIA on whole-slide images (WSI) of 302 surgically removed Ki67-stained breast cancer specimens; the tumour classifier algorithm was used to automatically detect tumour tissue but was not trained to distinguish between invasive and non-invasive carcinoma cells. The WSI DIA-generated data were subsampled by hexagonal tiling (HexT). Distribution and texture parameters were compared to conventional WSI DIA and pathology report data. Factor analysis of the data set, including total numbers of tumor cells, the Ki67 LI and Ki67 distribution, and texture indicators, extracted 4 factors, identified as entropy, proliferation, bimodality, and cellularity. The factor scores were further utilized in cluster analysis, outlining subcategories of heterogeneous tumors with predominant entropy, bimodality, or both at different levels of proliferative activity. The methodology also allowed the visualization of Ki67 LI heterogeneity in tumors and the automated detection and quantitative evaluation of Ki67 hotspots, based on the upper quintile of the HexT data, conceptualized as the "Pareto hotspot". We conclude that systematic subsampling of DIA-generated data into HexT enables comprehensive Ki67 LI analysis that reflects aspects of intra-tumor heterogeneity and may serve as a methodology to improve digital immunohistochemistry in general.

2.
Breast Cancer Res ; 16(2): R35, 2014.
Article in English | MEDLINE | ID: mdl-24708745

ABSTRACT

INTRODUCTION: Immunohistochemical Ki67 labelling index (Ki67 LI) reflects proliferative activity and is a potential prognostic/predictive marker of breast cancer. However, its clinical utility is hindered by the lack of standardized measurement methodologies. Besides tissue heterogeneity aspects, the key element of methodology remains accurate estimation of Ki67-stained/counterstained tumour cell profiles. We aimed to develop a methodology to ensure and improve accuracy of the digital image analysis (DIA) approach. METHODS: Tissue microarrays (one 1-mm spot per patient, n = 164) from invasive ductal breast carcinoma were stained for Ki67 and scanned. Criterion standard (Ki67-Count) was obtained by counting positive and negative tumour cell profiles using a stereology grid overlaid on a spot image. DIA was performed with Aperio Genie/Nuclear algorithms. A bias was estimated by ANOVA, correlation and regression analyses. Calibration steps of the DIA by adjusting the algorithm settings were performed: first, by subjective DIA quality assessment (DIA-1), and second, to compensate the bias established (DIA-2). Visual estimate (Ki67-VE) on the same images was performed by five pathologists independently. RESULTS: ANOVA revealed significant underestimation bias (P < 0.05) for DIA-0, DIA-1 and two pathologists' VE, while DIA-2, VE-median and three other VEs were within the same range. Regression analyses revealed best accuracy for the DIA-2 (R-square = 0.90) exceeding that of VE-median, individual VEs and other DIA settings. Bidirectional bias for the DIA-2 with overestimation at low, and underestimation at high ends of the scale was detected. Measurement error correction by inverse regression was applied to improve DIA-2-based prediction of the Ki67-Count, in particularfor the clinically relevant interval of Ki67-Count < 40%. Potential clinical impact of the prediction was tested by dichotomising the cases at the cut-off values of 10, 15, and 20%. Misclassification rate of 5-7% was achieved, compared to that of 11-18% for the VE-median-based prediction. CONCLUSIONS: Our experiments provide methodology to achieve accurate Ki67-LI estimation by DIA, based on proper validation, calibration, and measurement error correction procedures, guided by quantified bias from reference values obtained by stereology grid count. This basic validation step is an important prerequisite for high-throughput automated DIA applications to investigate tissue heterogeneity and clinical utility aspects of Ki67 and other immunohistochemistry (IHC) biomarkers.


Subject(s)
Breast Neoplasms/metabolism , Carcinoma, Ductal, Breast/metabolism , Image Processing, Computer-Assisted/methods , Immunohistochemistry/methods , Ki-67 Antigen/analysis , Algorithms , Analysis of Variance , Breast Neoplasms/diagnosis , Carcinoma, Ductal, Breast/diagnosis , Cell Proliferation , Female , Humans , Immunohistochemistry/instrumentation , Linear Models , Mitotic Index , Prognosis , Reproducibility of Results , Sensitivity and Specificity , Tissue Array Analysis/methods
3.
Diagn Pathol ; 9 Suppl 1: S10, 2014.
Article in English | MEDLINE | ID: mdl-25565007

ABSTRACT

BACKGROUND: Digital immunohistochemistry (IHC) is one of the most promising applications brought by new generation image analysis (IA). While conventional IHC staining quality is monitored by semi-quantitative visual evaluation of tissue controls, IA may require more sensitive measurement. We designed an automated system to digitally monitor IHC multi-tissue controls, based on SQL-level integration of laboratory information system with image and statistical analysis tools. METHODS: Consecutive sections of TMA containing 10 cores of breast cancer tissue were used as tissue controls in routine Ki67 IHC testing. Ventana slide label barcode ID was sent to the LIS to register the serial section sequence. The slides were stained and scanned (Aperio ScanScope XT), IA was performed by the Aperio/Leica Colocalization and Genie Classifier/Nuclear algorithms. SQL-based integration ensured automated statistical analysis of the IA data by the SAS Enterprise Guide project. Factor analysis and plot visualizations were performed to explore slide-to-slide variation of the Ki67 IHC staining results in the control tissue. RESULTS: Slide-to-slide intra-core IHC staining analysis revealed rather significant variation of the variables reflecting the sample size, while Brown and Blue Intensity were relatively stable. To further investigate this variation, the IA results from the 10 cores were aggregated to minimize tissue-related variance. Factor analysis revealed association between the variables reflecting the sample size detected by IA and Blue Intensity. Since the main feature to be extracted from the tissue controls was staining intensity, we further explored the variation of the intensity variables in the individual cores. MeanBrownBlue Intensity ((Brown+Blue)/2) and DiffBrownBlue Intensity (Brown-Blue) were introduced to better contrast the absolute intensity and the colour balance variation in each core; relevant factor scores were extracted. Finally, tissue-related factors of IHC staining variance were explored in the individual tissue cores. CONCLUSIONS: Our solution enabled to monitor staining of IHC multi-tissue controls by the means of IA, followed by automated statistical analysis, integrated into the laboratory workflow. We found that, even in consecutive serial tissue sections, tissue-related factors affected the IHC IA results; meanwhile, less intense blue counterstain was associated with less amount of tissue, detected by the IA tools.


Subject(s)
Biomarkers, Tumor/metabolism , Breast Neoplasms/pathology , Clinical Laboratory Information Systems , Image Processing, Computer-Assisted , Algorithms , Female , Humans , Immunohistochemistry , Staining and Labeling , Tissue Array Analysis
4.
Diagn Pathol ; 9 Suppl 1: S8, 2014.
Article in English | MEDLINE | ID: mdl-25565221

ABSTRACT

BACKGROUND: Digital image analysis (DIA) enables better reproducibility of immunohistochemistry (IHC) studies. Nevertheless, accuracy of the DIA methods needs to be ensured, demanding production of reference data sets. We have reported on methodology to calibrate DIA for Ki67 IHC in breast cancer tissue based on reference data obtained by stereology grid count. To produce the reference data more efficiently, we propose digital IHC wizard generating initial cell marks to be verified by experts. METHODS: Digital images of proliferation marker Ki67 IHC from 158 patients (one tissue microarray spot per patient) with an invasive ductal carcinoma of the breast were used. Manual data (mD) were obtained by marking Ki67-positive and negative tumour cells, using a stereological method for 2D object enumeration. DIA was used as an initial step in stereology grid count to generate the digital data (dD) marks by Aperio Genie and Nuclear algorithms. The dD were collected into XML files from the DIA markup images and overlaid on the original spots along with the stereology grid. The expert correction of the dD marks resulted in corrected data (cD). The percentages of Ki67 positive tumour cells per spot in the mD, dD, and cD sets were compared by single linear regression analysis. Efficiency of cD production was estimated based on manual editing effort. RESULTS: The percentage of Ki67-positive tumor cells was in very good agreement in the mD, dD, and cD sets: regression of cD from dD (R2=0.92) reflects the impact of the expert editing the dD as well as accuracy of the DIA used; regression of the cD from the mD (R2=0.94) represents the consistency of the DIA-assisted ground truth (cD) with the manual procedure. Nevertheless, the accuracy of detection of individual tumour cells was much lower: in average, 18 and 219 marks per spot were edited due to the Genie and Nuclear algorithm errors, respectively. The DIA-assisted cD production in our experiment saved approximately 2/3 of manual marking. CONCLUSIONS: Digital IHC wizard enabled DIA-assisted stereology to produce reference data in a consistent and efficient way. It can provide quality control measure for appraising accuracy of the DIA steps.


Subject(s)
Breast Neoplasms/pathology , Ki-67 Antigen/analysis , Algorithms , Calibration , Female , Humans , Image Processing, Computer-Assisted/standards , Immunohistochemistry/standards , Linear Models , Quality Control , Reproducibility of Results
5.
Int J Gynecol Pathol ; 30(5): 452-9, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21804396

ABSTRACT

Most adult granulosa cell tumors (AGCTs) consist of small-to-medium cells with scanty cytoplasm imparting a "small blue cell" appearance. We report 9 cases of luteinized AGCT, whose appearance differs from typical AGCT by the presence of abundant eosinophilic cytoplasm in at least 50% of tumor cells. These tumors were identified in patients aged between 37 and 80 years, all but 1 of whom were postmenopausal. The tumors ranged in size from 4.4 to 14 cm, usually had a yellow cut surface, were unilateral in 7 cases, bilateral in 1 case, and presented as a pelvic mass posthysterectomy in 1 case. Endometrial proliferative changes were present in 7 of 7 (100%) of the postmenopausal patients, a higher percentage than that reported in typical AGCT. The luteinized component occupied 50% to 90% of the tumors that were examined. Morphologic differences from typical AGCT were the luteinization of cytoplasm, relative lack of nuclear grooves, the presence of prominent nucleoli, and a myxoid stroma. The luteinized areas, especially when widespread, resulted in consideration of a wide range of other primary and metastatic ovarian neoplasms containing oxyphilic cells. Immunohistochemistry was useful in confirming a sex cord-stromal tumor, but of no value in the distinction from other neoplasms in the same category. Pathologists should be aware of the existence of luteinized AGCT, an uncommon variant of AGCT, to avoid an erroneous diagnosis.


Subject(s)
Granulosa Cell Tumor/pathology , Adult , Aged , Aged, 80 and over , Female , Humans , Luteal Cells/pathology , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...